Novo Nordisk’s growth spurt in Kalundborg, Denmark, is ostensibly still ongoing.
A number of Danish media, including SN.dk, are reporting that the firm is investing DKK 1bn (USD 143.8m) in building one new factory and upgrading two production facilities in the Danish city.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.
Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Coloplast's climate goals approved by international initiative
The Science Based Targets initiative has approved Coloplast’s carbon emission reduction goals.
Top news from MedWatch this week
Miss anything?
Corporate Quality Compliance Specialist for Audit Management 
Open position for a Clinical Trial Manager to join our team at Nykode! 
Project Managers keep all of us healthy 
Scientific Writer 
Senior Manager/Associate Director, Global Regulatory Affairs, CMC 
Chair of the Board 
Principal Laboratory Technologist Medicinal Chemistry 
Senior Toxicologist 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Global Learning Specialist 
Director Regulatory Affairs